

Joseph M Unger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4880812/publications.pdf>

Version: 2024-02-01

122
papers

10,997
citations

38660

50
h-index

30848

102
g-index

124
all docs

124
docs citations

124
times ranked

12545
citing authors

#	ARTICLE	IF	CITATIONS
1	Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials. <i>New England Journal of Medicine</i> , 1999, 341, 2061-2067.	13.9	2,030
2	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 923-932.	13.9	452
3	The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 185-198.	1.8	375
4	New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 8447-8452.	0.8	368
5	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. <i>JAMA Oncology</i> , 2019, 5, e191870.	3.4	348
6	Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 1681-1690.	13.9	298
7	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> , 2004, 103, 4251-4258.	0.6	296
8	Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. <i>Journal of the National Cancer Institute</i> , 2019, 111, 245-255.	3.0	294
9	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 1981-1990.	0.8	268
10	Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014. <i>Journal of Clinical Oncology</i> , 2008, 26, 2258-2263.	0.8	247
11	The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 185-198.	1.8	246
12	Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516. <i>The Southwest Oncology Group. Journal of Clinical Oncology</i> , 2009, 27, 114-119.	0.8	226
13	Patient Income Level and Cancer Clinical Trial Participation. <i>Journal of Clinical Oncology</i> , 2013, 31, 536-542.	0.8	209
14	Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2002, 20, 2058-2066.	0.8	206
15	Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 167.	3.8	202
16	Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 2067-2075.	0.8	197
17	Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2627-2633.	0.8	184
18	Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju002.	3.0	178

#	ARTICLE	IF	CITATIONS
19	A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. <i>Blood</i> , 2003, 102, 1606-1612.	0.6	165
20	Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin's Disease. <i>Journal of Clinical Oncology</i> , 2001, 19, 4238-4244.	0.8	143
21	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). <i>Journal of Clinical Oncology</i> , 2020, 38, 804-814.	0.8	142
22	Health-Related Quality of Life Results in Pathologic Stage C Prostate Cancer From a Southwest Oncology Group Trial Comparing Radical Prostatectomy Alone With Radical Prostatectomy Plus Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 112-120.	0.8	140
23	A phase 2 trial of complete resection for stage IV melanoma. <i>Cancer</i> , 2011, 117, 4740-4746.	2.0	136
24	Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. <i>JAMA Network Open</i> , 2018, 1, e181235.	2.8	130
25	Patient Income Level and Cancer Clinical Trial Participation. <i>JAMA Oncology</i> , 2016, 2, 137.	3.4	123
26	“When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 244-257.	3.0	116
27	Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. <i>JAMA Oncology</i> , 2019, 5, 326.	3.4	115
28	Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 141-144.	0.8	105
29	Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 1474-1486.	0.8	102
30	Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897. <i>Journal of Clinical Oncology</i> , 2009, 27, 2157-2162.	0.8	100
31	Risk Assessment in Localized Primary Cutaneous Melanoma. <i>American Journal of Clinical Pathology</i> , 2002, 118, 504-511.	0.4	98
32	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 54-63.	3.0	98
33	A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316). <i>Oncologist</i> , 2012, 17, 1180-1190.	1.9	89
34	Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2010, 95, 597-603.	1.7	87
35	A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. <i>Leukemia and Lymphoma</i> , 2009, 50, 728-735.	0.6	84
36	Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. <i>Journal of Clinical Oncology</i> , 2015, 33, 1910-1917.	0.8	83

#	ARTICLE	IF	CITATIONS
37	Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 453.	3.4	83
38	Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. <i>Journal of Clinical Oncology</i> , 2018, 36, 326-332.	0.8	79
39	Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897. <i>Journal of Clinical Oncology</i> , 2008, 26, 1223-1230.	0.8	78
40	Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin's Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809. <i>Journal of Clinical Oncology</i> , 2000, 18, 2010-2016.	0.8	74
41	Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2013, 119, 371-379.	2.0	74
42	Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2010651.	2.8	72
43	Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. <i>Journal of the National Cancer Institute</i> , 2019, 111, 210-213.	3.0	70
44	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. <i>Blood</i> , 2005, 107, 1101-1107.	0.6	68
45	Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. <i>JAMA Oncology</i> , 2019, 5, 497.	3.4	67
46	Impact of a Peer-Delivered Telephone Intervention for Women Experiencing a Breast Cancer Recurrence. <i>Journal of Clinical Oncology</i> , 2007, 25, 2093-2099.	0.8	62
47	Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 1339-1348.	0.8	62
48	Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2710-2717.	0.8	61
49	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa034.	1.4	59
50	Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. <i>Journal of Clinical Oncology</i> , 2020, 38, 2122-2129.	0.8	59
51	Metastatic Melanoma From Intraocular Primary Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 568-572.	0.6	59
52	The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trial. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 529-539.	2.0	55
53	Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. <i>Laboratory Investigation</i> , 2007, 87, 979-997.	1.7	50
54	Cross-Sectional Versus Longitudinal Estimates of Cognitive Change in Nondemented Older People: A CERAD Study. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 559-563.	1.3	45

#	ARTICLE	IF	CITATIONS
55	The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. <i>JAMA Oncology</i> , 2016, 2, 875.	3.4	45
56	HIV-Related Stigma and Viral Suppression Among African-American Women: Exploring the Mediating Roles of Depression and ART Nonadherence. <i>AIDS and Behavior</i> , 2019, 23, 2025-2036.	1.4	43
57	Estimated impact of the Prostate Cancer Prevention Trial on population mortality. <i>Cancer</i> , 2005, 103, 1375-1380.	2.0	40
58	Ovarian Protection during Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 2268-2270.	13.9	39
59	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). <i>Breast Cancer Research and Treatment</i> , 2018, 172, 603-610.	1.1	37
60	The COVID-19 pandemic and new clinical trial activations. <i>Trials</i> , 2021, 22, 260.	0.7	37
61	Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw168.	3.0	36
62	Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 131.	3.4	36
63	Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2118433.	2.8	35
64	Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research Program. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 669-675.	1.1	35
65	Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 246.	3.4	34
66	CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. <i>British Journal of Haematology</i> , 2014, 166, 382-389.	1.2	33
67	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP Rituximab versus CHOP + 131Iodine Tositumomab. <i>Clinical Cancer Research</i> , 2013, 19, 6624-6632.	3.2	32
68	Supplement use during an intergroup clinical trial for breast cancer (S0221). <i>Breast Cancer Research and Treatment</i> , 2013, 137, 903-913.	1.1	31
69	Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups. <i>Cancer</i> , 2019, 125, 1313-1318.	2.0	30
70	Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 750-755.	0.8	29
71	Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings. <i>JAMA Network Open</i> , 2020, 3, e203842.	2.8	29
72	S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 372-380.	3.0	28

#	ARTICLE	IF	CITATIONS
73	Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare. <i>Blood Cancer Discovery</i> , 2021, 2, 119-124.	2.6	27
74	Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). <i>Blood</i> , 2008, 111, 4048-4054.	0.6	25
75	Effect of Adding Rituximab to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).. <i>Blood</i> , 2004, 104, 158-158.	0.6	25
76	The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population. <i>JAMA Oncology</i> , 2017, 3, 1345.	3.4	24
77	Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 66-78.	1.8	23
78	Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 804-805.	0.8	20
79	Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202. <i>Cancer</i> , 2019, 125, 2123-2129.	2.0	18
80	Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. <i>JAMA Network Open</i> , 2019, 2, e1910593.	2.8	18
81	Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. <i>Cancer Medicine</i> , 2020, 9, 2146-2152.	1.3	18
82	Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. <i>Blood</i> , 2015, 125, 236-241.	0.6	17
83	The Diffusion of Docetaxel in Patients With Metastatic Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	17
84	Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1208-1215.	3.0	16
85	What Keeps Patients Out of Clinical Trials?. <i>JCO Oncology Practice</i> , 2020, 16, 125-127.	1.4	16
86	Religiosity, Social Support, and Ethnic Identity: Exploring Resilience Resources for African-American Women Experiencing HIV-Related Stigma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 175-183.	0.9	14
87	A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 98-98.	0.6	14
88	The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies†. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 362-368.	0.8	13
89	Caregiver engagement practices in National Cancer Institute Clinical Oncology Research Program settings: Implications for research to advance the field. <i>Cancer</i> , 2021, 127, 639-647.	2.0	13
90	Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2021, 113, 989-996.	3.0	13

#	ARTICLE	IF	CITATIONS
91	Patterns of alcohol use and associated characteristics and HIV-related outcomes among a sample of African-American women living with HIV. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107753.	1.6	12
92	Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls. <i>Frontiers in Pharmacology</i> , 2021, 12, .	1.6	12
93	Sociodemographic, clinical and birth hospitalization characteristics and infant Hepatitis B vaccination in Washington State. <i>Vaccine</i> , 2019, 37, 5738-5744.	1.7	11
94	Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 324-330.	0.8	11
95	Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years. <i>Cancer</i> , 2021, 127, 4574-4584.	2.0	11
96	Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 27.	0.9	10
97	Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2031202.	2.8	10
98	A Strategy for Full Interrogation of Prognostic Gene Expression Patterns: Exploring the Biology of Diffuse Large B Cell Lymphoma. <i>PLoS ONE</i> , 2011, 6, e22267.	1.1	9
99	Unequal impact of the COVID-19 pandemic on paediatric cancer care: a population-based cohort study in China. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 19, 100347.	1.3	9
100	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342.	0.8	9
101	Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials. <i>JCO Oncology Practice</i> , 2021, 17, e1246-e1257.	1.4	8
102	Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7010-7010.	0.8	8
103	Estimating global treatment toxicity burden from adverse event data. <i>Cancer</i> , 2018, 124, 858-864.	2.0	7
104	Lung Cancer Screening in the National Cancer Institute Community Oncology Research Program: Availability and Service Organization. <i>Journal of the American College of Radiology</i> , 2019, 16, 427-434.	0.9	7
105	Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 455-463.	1.1	5
106	Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. <i>JCO Oncology Practice</i> , 2022, 18, e442-e451.	1.4	5
107	Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. <i>Contemporary Clinical Trials</i> , 2020, 95, 106037.	0.8	4
108	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). <i>JCO Oncology Practice</i> , 2021, 17, e1821-e1829.	1.4	4

#	ARTICLE	IF	CITATIONS
109	Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211.. Journal of Clinical Oncology, 2019, 37, 11502-11502.	0.8	4
110	Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. Journal of Cancer Survivorship, 2017, 11, 32-40.	1.5	3
111	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. Cancer Epidemiology, 2018, 55, 117-122.	0.8	3
112	Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105).. Journal of Clinical Oncology, 2020, 38, 12019-12019.	0.8	3
113	"Minority report": how best to analyze clinical trial data to address disparities. Breast Cancer Research and Treatment, 2009, 118, 519-521.	1.1	2
114	Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology"Reply. JAMA Oncology, 2016, 2, 1511.	3.4	2
115	A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events. Health and Quality of Life Outcomes, 2019, 17, 146.	1.0	2
116	Economic Evaluations in National Cancer Institute's Sponsored Network Cancer Clinical Trials. Value in Health, 2020, 23, 1653-1661.	0.1	2
117	Long-term results from a randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in early stage breast cancer (S1200).. Journal of Clinical Oncology, 2021, 39, 12018-12018.	0.8	2
118	Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms. JNCI Cancer Spectrum, 2021, 5, pkab087.	1.4	2
119	History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials. JCO Clinical Cancer Informatics, 2017, 1, 1-12.	1.0	1
120	Representativeness in Premarketing vs Postmarketing US Food and Drug Administration Trials. JAMA Network Open, 2021, 4, e217159.	2.8	1
121	Patterns of Scientific and Clinical Impact in Cancer Randomized Clinical Trials. JAMA Network Open, 2022, 5, e2219657.	2.8	1
122	Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer"Reply. JAMA Oncology, 2016, 2, 686.	3.4	0